Novavax, Inc. (NVAX) Stock Forecast
Data as of Jun 17, 2026Healthcare · Current price $9.29 (+0.63%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Oct 23, 2025 | Sean Lee | H.C. Wainwright | $11.00 | +18.4% |
| Nov 18, 2024 | Mayank Mamtani | B.Riley Financial | $22.00 | +136.8% |
| Oct 16, 2024 | Roger Song | Jefferies | $25.00 | +169.1% |
| Oct 16, 2024 | Alec Stranahan | Bank of America Securities | $14.00 | +50.7% |
| Jul 19, 2024 | Roger Song | Jefferies | $31.00 | +233.7% |
| May 10, 2024 | Vernon Bernardino | H.C. Wainwright | $19.00 | +104.5% |
| Feb 14, 2022 | Charles Duncan | Cantor Fitzgerald | $174.00 | +1773.0% |
Top Analysts Covering NVAX
NVAX vs Sector & Market
| Metric | NVAX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.25 | 2.24 | 2.40 |
| Analyst Count | 4 | 8 | 19 |
| Target Upside | +103.7% | +11474.9% | +17.1% |
| P/E Ratio | 3.89 | 3.91 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $81M | $87M | $96M | 4 |
| 2026-09-30 | $98M | $132M | $181M | 2 |
| 2026-12-31 | $102M | $138M | $189M | 3 |
| 2027-03-31 | $9M | $13M | $17M | 3 |
| 2027-06-30 | $8M | $10M | $14M | 2 |
| 2027-09-30 | $193M | $262M | $357M | 2 |
| 2027-12-31 | $110M | $148M | $202M | 3 |
| 2028-12-31 | $350M | $350M | $350M | 4 |
| 2029-12-31 | $210M | $353M | $474M | 3 |
| 2030-12-31 | $270M | $454M | $610M | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-0.14 | $-0.13 | $-0.11 | 4 |
| 2026-09-30 | $-0.01 | $-0.01 | $-0.01 | 1 |
| 2026-12-31 | $0.01 | $0.01 | $0.02 | 2 |
| 2027-03-31 | $-0.62 | $-0.42 | $-0.28 | 2 |
| 2027-06-30 | $-0.52 | $-0.35 | $-0.23 | 1 |
| 2027-09-30 | $0.69 | $1.04 | $1.53 | 1 |
| 2027-12-31 | $0.30 | $0.46 | $0.68 | 2 |
| 2028-12-31 | $-0.46 | $0.26 | $0.86 | 4 |
| 2029-12-31 | $0.16 | $0.33 | $0.48 | 2 |
| 2030-12-31 | $0.42 | $0.90 | $1.30 | 2 |
Frequently Asked Questions
What is the analyst consensus for NVAX?
The consensus among 4 analysts covering Novavax, Inc. (NVAX) is Buy with an average price target of $18.00.
What is the highest price target for NVAX?
The highest price target for NVAX is $174.00, set by Charles Duncan at Cantor Fitzgerald on 2022-02-14.
What is the lowest price target for NVAX?
The lowest price target for NVAX is $11.00, set by Sean Lee at H.C. Wainwright on 2025-10-23.
How many analysts cover NVAX?
4 analysts have issued ratings for Novavax, Inc. in the past 12 months.
Is NVAX a buy or sell right now?
Based on 4 analyst ratings, NVAX has a consensus rating of Buy (2.25/5) with a +103.7% upside to the consensus target of $18.00.
What are the earnings estimates for NVAX?
Analysts estimate NVAX will report EPS of $-0.13 for the period ending 2026-06-30, with revenue estimated at $87M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.